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Introduction 
Invasive pulmonary aspergillosis (IPA) occurs almost 
exclusively in patients with profound neutropenia (l), often 
secondary to the cytotoxic therapy used in the treatment of 
haematological malignancy or patients undergoing organ 
transplantation. Patients with severe defects in cell- 
mediated immunity may also develop IPA (2). More rarely, 
cases have been reported in non-immunocompromised 
individuals, associated with alcoholism, diabetes mellitus, 
steroid therapy and influenza virus infection (3-7). Mor- 
tality in patients with invasive aspergillosis may be as high 
as 90% despite antifungal therapy (8-12). We report a 
patient with diabetic ketoacidosis, who rapidly developed 
respiratory problems, but with early diagnosis of invasive 
pulmonary aspergillosis and aggressive treatment with dual 
antifungal therapy he survived, although he required 57 
days in ITU. 
Case Report 
A 45-year-old insulin-dependent diabetic was admitted to 
hospital with a 1 week history of a ‘flu-like’ illness. In the 
24 h prior to hospital admission he had become pyrexial 
with vomiting and confusion and consequently omitted his 
insulin. He had a past medical history of hypertension 
treated with enalapril, drank 10 units of alcohol per week, 
and had not taken antibiotics or steroids within the last 
year. 
On admission his temperature was 38”C, pulse 100 min- ‘, 
blood pressure 120/70, and was ketotic. Glasgow Coma 
Scale (GCS) was 9115. His chest was clear and he had no 
focal neurology. 
Initial blood electrolytes were as follows: sodium 
140 mm01 1 - ’ (normal range 134-145), potassium 
5.4 mm01 1 - ’ (3.5-5.0), urea 42 mmol 1 - ’ (3&6.7), creati- 
nine 393 pm011 - ’ (7G-120) and glucose 72 mm01 l- ’ (3.5- 
10.0). Arterial blood gas (ABG) pH 7.14 PaCO, 26 mmHg, 
PaO, 102 mmHg, bicarbonate 9 mmol l- ’ (22-30). Full 
blood count, clotting screen, electrocardiograph and initial 
chest X-ray appearance were normal. 
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PLATE 1. Chest radiograph from day 5 showing patchy 
consolidation and volume loss in the left lower zone 
with loss of definition of the left heart border indicating 
lingular involvement. 
He was diagnosed and treated as a diabetic ketoacidosis, 
with intravenous fluid and insulin. Intravenous cefotaxime, 
flucloxacillin and metronidazole were commenced because 
of his pyrexia and possible aspiration. Although blood 
sugar, urea and acidosis all gradually corrected over the 
next 24 h, the sodium gradually rose to 175 mm01 1 - I at 
which time he was again noted to be confused with a 
deteriorating GCS and required elective ventilation for a 
compromised airway. The hypernatraemia was corrected 
over 4 days associated with a slow neurological recovery. A 
computed tomography-scan of head and ultrasound of 
kidneys were both normal. 
Over this period the pyrexia continued despite intra- 
venous antibiotics. Blood and urine cultures were negative. 
Bilaterial antral washouts were performed for persistent 
nasal discharge and purulent material drained from the left 
maxillary sinus. By day 5 he became progressively more 
hypoxic and developed left-sided chest signs. The repeat 
chest X-ray showed new patchy consolidation in the left 
lower zone (Plate 1). The antibiotics were changed to 
piperacillin, gentamicin and metronidazole. As Can&& 
albicans had been isolated from endotracheal aspirates 
taken on day 2 and day 3 of the admission, and from the 
antral washouts, intravenous fluconazole was commenced. 
Bronchoscopy was performed, and showed thick white 
plaques over the left main bronchus extending into left 
upper and lower lobe bronchi, thought to be consistent with 
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PLATE 2. Magnification x 200, periodic acid-Schiff stain. 
Bronchial biopsy specimen showing connective tissue 
infiltrated by a mass of fungal hyphae which are both 
branching and septate and consistent with aspergillus. 
candida. On day 7 Aspergillus fumigatus was isolated from 
endotracheal aspirates taken on day 4 and 5 and a repeat 
bronchoscopy was performed with bronchial biopsies. 
Chest X-ray appearance and gas exchange continued to 
deteriorate and fluconozole was replaced by oral itracona- 
zole 200,ug b.d. and amphotericin nebulizers 4Opg b.d. By 
day 10 A. fumigatus had been isolated from bronchial 
washings and invasive pulmonary aspergillosis was con- 
firmed by biopsy (Plate 2). In view of his impaired renal 
function intravenous amphotericin B colloidal dispersion 
(ABCD) [‘Amphocil’] was commenced at 2 mg kg - ’ daily 
increasing to 4 mg kg - ’ daily. 
The isolate A. fumigatus was sensitive to both ampho- 
tericin and itraconazole with minimum inhibitory concen- 
trations of 0.125 mg l- ’ and 0.25 mg l- ‘, respectively. 
Serum itraconazole levels taken 2 weeks after commencing 
therapy, and at intervals thereafter, were satisfactory. Sero- 
logical testing showed a strongly positive titre for influenza 
B virus (1:640). Other respiratory serology was negative. 
An HIV antibody test was negative and immunology was 
normal. Aspergillus precipitins were negative. Initially his 
chest X-ray continued to deteriorate (Plate 3) but after 57 
days ventilation and 37 days of ABCD, he was discharged 
from ITU. He later received a further 23 days of ABCD 
when A. fumigatus was again isolated from respiratory 
specimens. Itraconazole was continued for 6 months. He 
made a good clinical recovery and returned to full-time 
employment 3 months later. Discharge CT scans showed 
persistent scaring and cystic changes in the anterior segment 
of the upper lob (Plate 4). 
Discussion 
Aspergillus sp. are ubiquitous environmental fungi. Inhala- 
tion of air-borne conidia may result in harmless coloniz- 
ation of the respiratory tract, aspergilloma formation, 
allergic bronchopulmonary aspergillosis or invasive pul- 
monary aspergillosis. The incidence of invasive disease is 
PLATE 3. Chest radiograph taken 1 month after admission 
showing extension of the consolidation to involve all the 
lingular and at least part of the upper lobe. 
PLATE 4. CT-scan of the chest at discharge showing 
persistent scarring and cystic changes in the anterior 
segment of the upper lobe. 
variable and unpredictable, even in the highest-risk neutro- 
penic population. 
This is an unusual case of a non-immunocompromised 
patient developing, most probably, hospital-acquired inva- 
sive pulmonary aspergillosis (IPA). Of the 39 previously 
reported cases (4-6,13%19) of non-immunocompromised 
patients with IPA only three were diabetic and all were 
non-insulin dependent (5,6,13). Five of the 39 cases had 
concurrent influenza virus infection, all type A unlike our 
type B (4,5,16,18,19). Influenza possibly predisposes to IPA 
via damage to the respiratory mucosa. or suppression of 
cell-mediated immunity (20). 
Opportunistic infections are more common in patients 
with diabetes mellitus, particularly insulin-dependent dia- 
betics, with one or more major complication of the disease. 
In vitro studies have shown decreased leukocyte bactericidal 
activity and impaired macrophage mobility and phagocytic 
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TABLE 1. Table of predisposing factors as previously 
described in 39 non-immunocompromised patients diag- 
nosed as having IPA. Mean age 52 years (range 22-81) 
Predisposing factor 
Number 
of cases 
Steroids (used for underlying chest disease) 8 
Diabetes 3 
Influenza 5 
Alcohol 5 
Underlying chest disease 13 
Other organ failure - one renal/one cardiac 2 
Total of 26 of the 39 patients having one or more predis- 
posing factors. 
capacity (6). These factors, which are all involved in 
immune defence against fungal invasion (21) may predis- 
pose diabetics to infection. Table 1 shows possible predis- 
posing factors found in non-immunocompromised patients 
with invasive pulmonary aspergillosis and the number of 
associated cases. 
Aggressive approaches to lung biopsy in immunocom- 
promised hosts with ‘fever and pulmonary infiltrate’ syn- 
dromes, expedite diagnosis of fungal pneumonias and may 
improve the high morbidity and mortality (22-24). This 
patient was bronchoscoped 1 day after his chest X-ray 
deterioration and started on antifungal treatment within 
48 h, with optimal chemotherapy commencing 48 h later 
following biopsy confirmation of the diagnosis. 
The isolation of Aspergillus sp. in respiratory specimens 
may represent colonization, and is not diagnostic of 
infection per se. Indeed air-borne contamination both 
of specimens at the point of collection, and within the 
laboratory, must also be considered. A previous study 
of sputum samples and bronchial washings of non- 
immunocompromised patients with fever and patchy pul- 
monary infiltrates showed that of 10 patients whose sputa 
grew Aspergillus sp. two were later proven to have IPA (a 
20% specificity); and of five patients in whom bronchial 
washings grew Aspergillus sp., again two were later shown 
to have invasive disease (a 40% specificity) (4). Although 
the diagnosis of IPA is dependent on histological confirma- 
tion of tissue invasion by the characteristic septate hyphae 
(25) the above study suggests that growth of Aspergillus sp. 
from respiratory secretions of patients with patchy consoli- 
dation, not responding to antibiotics, should encourage 
early bronchoscopy with fungal cultures of both lavage 
fluid and biopsy specimens plus histology. Although 
aspergillus precipitins are usually positive in the allergic 
form of the disease, and in aspergilloma, they are not 
helpful in the diagnosis of invasive disease, and serological 
tests for circulating aspergillus antigens are of limited 
diagnostic value. 
The treatment of choice for invasive aspergillus infection 
is amphotericin B. Several amphotericin preparations are 
now available permitting the use of much higher daily and 
total doses (over 20 g in this patient). Itraconazole, 
although active against Aspergillus sp., was, at this time, 
only available in oral formulation. Concern has been 
expressed about poor absorption and hence sub-optimal 
serum and tissue levels (26). Denning et al. (27) report a 
11% clinical, radiographical and mycological cure in 51 
patients with invasive aspergillosis treated with itraconazole 
alone. Six of these patients were non-immunocompromised 
with total cure in three cases. Fluconazole has negligible 
activity in these infections. 
This case illustrates an unusual complication of diabetes 
mellitus and it is likely that the combination of recent 
influenza B combined with diabetic ketoacidosis provided 
the setting for colonization and subsequent invasion of the 
bronchi by aspergillus. His fever was never adequately 
explained and hence an aggressive approach to diagnosis 
was adopted. It would appear that early intervention, 
confirming the diagnosis of invasive pulmonary aspergillo- 
sis, and initiating early treatment with dual therapy of 
ABCD and itraconazole have led to a full recovery of this 
patient despite a prolonged stay in ITU. He remains 
with left upper lobe bronchiectasis and possibly the risk 
of aspergilloma in the future and will continue to be 
monitored. 
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Endobronchial non-Hodgkin’s lymphoma 
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Introduction 
Non-Hodgkin’s lymphomas are a heterogeneous group of 
lymphoproliferative malignancies with different behaviour 
patterns, prognosis and management. 
Non-Hodgkin’s lymphoma involves the thoracic struc- 
tures, particularly the mediastinum and lung parenchyma, 
in up to 43% of patients at some stage in the course of 
their disease (1). Endobronchial involvement, however, is 
extremely rare, even in the presence of advanced disease. 
The first report of endobronchial non-Hodgkin’s lym- 
phoma was made by Dawe in 1955 (2). Since this time 
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less than 50 cases have been described in the literature 
(3-6). 
We report a further case and review the relevant literature. 
Case Report 
A 56-year-old man presented with a 3 months’ history of 
dyspnoea and productive cough. He had experienced 5 kg 
weight loss in the preceding year, mild night sweats, but no 
associated fevers. He had a 40 pack-year smoking history. 
The chest radiograph showed consolidation at the right 
lower and middle lobes with widened mediastinum sugges- 
tive of lymphadenopathy (Plate 1). Computed tomography 
(CT) scan of the chest demonstrated extensive mediastinal 
and right hilar lymphadenopathy, distal parenchymal con- 
solidation in the right lower lobe and a large right basal 
pleural fluid collection. 
